RYTM Christopher Paul German sells $139K worth of shares
Jun 13, 2025, 4:37 AM
0.00%
What does RYTM do
Rhythm Pharmaceuticals, based in Boston, develops therapeutics for rare diseases, focusing on melanocortin-4 receptor agonists like IMCIVREE, approved for chronic weight management in specific obesity cases. The company employs 226 people and went public in October 2017.
Christopher Paul German sold 2,069 shares of RYTM on 10 June at $67.19 per share, worth a total of $139K. They now own 1,889 RYTM shares, or a 52% holding decrease.
📡️ Health Care
Insider Trades
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.